Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment

Baroudi, Olfa; Baroudi, Thouraya; Omrane, Ines; Moussa, Amel; Mezlini, Amel; Ayari, Hajer; Guermazi, Sami; Bahloul, Abdesslem; Bouzaienne, Hassen; Uhrhammer, Nancy; Bignon, Yves; El-Gaaied, Amel; Bougatef, Karim
February 2014
Medical Oncology;Feb2014, Vol. 31 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • The changing face of chemotherapy in colorectal cancer. Waters, J; Cunningham, D // British Journal of Cancer;1/1/2001, Vol. 84 Issue 1, p1 

    Discusses improvements in the application of cytotoxic chemotherapy in treatments of colorectal cancer. Use of fluorouracils in the treatment of the cancer; Role of thymidylate synthase inhibitors in improving the treatment; Use of compounds with single-agent activity in the treatment.

  • Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Marcuello, E.; Altés, A.; Menoyo, A.; del Rio, E.; Baiget, M. // Cancer Chemotherapy & Pharmacology;Jun2006, Vol. 57 Issue 6, p835 

    Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) may play a central role in the action of 5-FU, an inhibitor of thymidylate synthase, by converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The aim of this...

  • Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Ichikawa, Wataru // Gastric Cancer;Sep2006, Vol. 9 Issue 3, p145 

    Fluoropyrimidines are widely used in chemotherapy regimens for metastatic gastric cancer. Interindividual variation in the enzyme activity of the 5-fluorouracil (FU) metabolic pathway can affect the extent of 5-FU metabolism and affect the efficacy of 5-FU based chemotherapy. In this review, the...

  • Can we predict response to 5-FU? McCann, Jean; McCann, J // JNCI: Journal of the National Cancer Institute;12/20/2000, Vol. 92 Issue 24, p1976 

    Examines the possibility of predicting response to treatment of 5-fluorouracil in patients with colorectal cancer. Importance of thymidylate synthase (TS) in the production of DNA; Increase in TS levels with the severity of the disease; Relationship between TS expression and p53; Role of...

  • Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. Páez, David; Paré, Laia; Altés, Albert; Sancho-Poch, Francesc Josep; Petriz, Lourdes; Garriga, Jordi; Monill, Josep Maria; Salazar, Juliana; del Rio, Elisabeth; Barnadas, Agustí; Marcuello, Eugenio; Baiget, Montserrat // Journal of Cancer Research & Clinical Oncology;Nov2010, Vol. 136 Issue 11, p1681 

    Purpose: Chemoradiotherapy using 5-fluorouracil has shown to be effective treatment for rectal cancer. Thymidylate synthase (TS) is an important target enzyme for the fluoropyrimidines. However, the predictive role of TS levels in early stage rectal cancer is not yet well understood. We analyzed...

  • Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer. Komori, Shuji; Osada, Shinji; Yoshida, Kazuhiro // ISRN Oncology;2011, p1 

    5-fluorouracil (5-FU) is widely used in chemotherapy for gastric and colorectal cancer, but gemcitabine (GEM), and not 5-FU, is approved as a standard drug for use in pancreatic cancer. Interindividual variation in the enzyme activity of the GEM metabolic pathway can affect the extent of GEM...

  • Thymidylate Synthase: A Target for Combination Therapy and Determinant of Chemotherapeutic Response in Colorectal Cancer. Van Triest; Peters // Oncology;1999, Vol. 57 Issue 3, p179 

    In this review, we describe the role of thymidylate synthase (TS) as a determinant of chemotherapeutic response. TS is an essential enzyme for the de novo synthesis of thymidylate and subsequent DNA synthesis. TS has been used as a target for cancer chemotherapy in the development of...

  • Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pullarkat, S.T.; Stoehlmacher, J.; Ghaderi, V.; Xiong, Y-P; Ingles, S.A.; Sherrod, A.; Warren, R.; Tsao-Wei, D.; Groshen, S.; Lenz, H-J // Pharmacogenomics Journal;2001, Vol. 1 Issue 1, p65 

    Presents a study which suggested that genotyping for the thymidylate synthase polymorphism may have the potential to identify patients more likely to respond to 5-fluorouracil based chemotherapy. Method of the study; Results and discussion; Conclusion.

  • Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy. Mauritz, R.; Peters, G. J. // Current Pharmacogenomics;Mar2006, Vol. 4 Issue 1, p57 

    The antimetabolite 5-fluorouracil (5-FU) is widely used in combination treatment of patients with advanced stages of colorectal cancer. In the last decade, several studies focused on genetically determined variability in function of certain enzymes that are involved in the metabolism of...

  • Genetic predictors of toxicities to chemotherapy.  // Reactions Weekly;11/28/2009, Issue 1280, p3 

    The article discusses several studies which investigated genetic predictors of toxicities to chemotherapy. A study from Korea found that diarrhoea and grade 3-4 anaemia were more frequent in patients with a thymidylate synthase (TS) 3-unsaturated region deletion homozygote. Research by E....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics